Ann: Security Class Reinstatement to Quotation- OPTOB, page-115

Yep, that makes sense: OPT at $2.20 minus $1.00 (option exercise) minus $0.12 (cost for OPTOB) gives a profit of $1.08 per option. As I understand it, we can exercise the options anytime until 30 June 2026, so someone might pay a (small) premium on $1.08 if they believe they can gain some leverage/gearing on the prospect of further increases in OPT.

Anyway, I might as well be photoshopping winning lotto numbers as create yet another graph of uber profits.

Our best use of our time focus should be on quantifying the risks, particularly the replication of P2B and P3 success. Even if there is proven efficacy, say with a full line improvement, what else could get in the way of approval by the FDA?